TY - JOUR
T1 - Misregulated Wnt/β-catenin signaling to ovarian granulosa cell tumor development
AU - Boerboom, Derek
AU - Paquet, Marilene
AU - Hsieh, Minnie
AU - Liu, Jinsong
AU - Jamin, Soazik P.
AU - Behringer, Richard R.
AU - Sirois, Jean
AU - Taketo, Makoto M.
AU - Richards, Jo Anne S.
PY - 2005/10/15
Y1 - 2005/10/15
N2 - Misregulation of the Wnt/β-catenin signaling pathway is a hallmark of several forms of cancer. Components of the Wnt/β-catenin pathway are expressed in ovarian granulosa cells; nevertheless, its potential involvement in granulosa cell tumorigenesis has not been examined. To this end, human (n = 6) and equine (n = 18) granulosa cell tumors (GCT) were analyzed for β-catenin expression by immunohistochemistry. Unlike granulosa cells of normal ovaries, most (15 of 24) GCT samples showed nuclear localization of β-catenin, suggesting that activation of the Wnt/β-catenin pathway plays a role in the etiology of GCT. To confirm this hypothesis, Catnbflox(ex3)/+; Amhr2cre/+ mice that express a dominant stable β-catenin mutant in their granulosa cells were generated. These mice developed follicle-like structures containing disorganized, pleiomorphic granulosa by 6 weeks of age. Even in older mice, these follicle-like lesions grew no larger than the size of antral follicles and contained very few proliferating cells. Similar to corpora lutea, the lesions were highly vascularized, although they did not express the luteinization marker Cyp11a1. Catnbflox(ex3)/+; Amhr2cre/+ females were also found to be severely subfertile, and fewer corpora lutea were found to form in response to exogenous gonadotropin compared with control mice. In older mice, the ovarian lesions often evolved into GCT, indicating that they represent a pretumoral intermediate stage. The GCT in Catnb flox(ex3)/+; Amhr2cre/+ mice featured many histopathologic similarities to the human disease, and prevalence of tumor development attained 57% at 7.5 months of age. Together, these studies show a causal link between misregulated Wnt/β-catenin signaling and GCT development and provide a novel model system for the study of GCT biology.
AB - Misregulation of the Wnt/β-catenin signaling pathway is a hallmark of several forms of cancer. Components of the Wnt/β-catenin pathway are expressed in ovarian granulosa cells; nevertheless, its potential involvement in granulosa cell tumorigenesis has not been examined. To this end, human (n = 6) and equine (n = 18) granulosa cell tumors (GCT) were analyzed for β-catenin expression by immunohistochemistry. Unlike granulosa cells of normal ovaries, most (15 of 24) GCT samples showed nuclear localization of β-catenin, suggesting that activation of the Wnt/β-catenin pathway plays a role in the etiology of GCT. To confirm this hypothesis, Catnbflox(ex3)/+; Amhr2cre/+ mice that express a dominant stable β-catenin mutant in their granulosa cells were generated. These mice developed follicle-like structures containing disorganized, pleiomorphic granulosa by 6 weeks of age. Even in older mice, these follicle-like lesions grew no larger than the size of antral follicles and contained very few proliferating cells. Similar to corpora lutea, the lesions were highly vascularized, although they did not express the luteinization marker Cyp11a1. Catnbflox(ex3)/+; Amhr2cre/+ females were also found to be severely subfertile, and fewer corpora lutea were found to form in response to exogenous gonadotropin compared with control mice. In older mice, the ovarian lesions often evolved into GCT, indicating that they represent a pretumoral intermediate stage. The GCT in Catnb flox(ex3)/+; Amhr2cre/+ mice featured many histopathologic similarities to the human disease, and prevalence of tumor development attained 57% at 7.5 months of age. Together, these studies show a causal link between misregulated Wnt/β-catenin signaling and GCT development and provide a novel model system for the study of GCT biology.
UR - http://www.scopus.com/inward/record.url?scp=27144540097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27144540097&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-05-1024
DO - 10.1158/0008-5472.CAN-05-1024
M3 - Article
C2 - 16230381
AN - SCOPUS:27144540097
SN - 0008-5472
VL - 65
SP - 9206
EP - 9215
JO - Cancer Research
JF - Cancer Research
IS - 20
ER -